In order to discriminate between normal interindividual variabilities and traces from cancer, the situation in healthy individuals is of critical knowledge. Chronix were the first to investigate into cfDNA in healthy by using NGS and has now a large database, which can be compared to patients to detect and monitor cancer derived cfDNA.

Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, et al. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem 2015;61:239-48.

Read the full article on: